The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...
Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.
The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...
Researchers have identified a previously unknown inflammatory mechanism that may drive the aggressiveness and relapse of ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment.
The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback